Trial Profile
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Lamivudine; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PYRAMID
- 13 Nov 2018 Interim results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 29 Sep 2015 New trial record